Gastric acid inhibitors; impact on gastric and colon cancer
Year: 2004
Type: article
Abstract: To date, at least 6 epidemiological studies (2 cohort and 4 case controls) have reported on the issue of chronic H2RAs therapy (especially cimetidine and ranitidine) and the risk of gastric cancer. According to these studies gastric cancer risk is significantly higher only during the first year of H2RA initiation. The relative risk gastric cancer remains slightly higher over the first five years, but diminishes thereafter. These data do not support a direct correlation between chronic H2RA therapy and the development of gastric cancer. However, the above studies point out that chronic antisecretory therapy may either mask pre-existing neoplasm or delay the diagnosis and appropriate therapy of premalignant lesions of gastric mucosa. Thus, meticulous inspection and biopsies of the gastric mucosa are considered critical prior to treatment contemplation. Unfortunately, there are no epidemiological studies with regard to chronic PPI treatment and gastric cancer risk. However, data coming from many clinical studies, as well as daily clinical experience with PPI (omeprazole or lansoprazole) that were administered over a long period, do not suggest a rise in gastric cancer risk. On the contrary, there are cases of delayed diagnosis of gastric cancer in patients who had received empirical chronic PPI therapy.
Source: Annals of Gastroenterology
Authors: J.F. Robotis, Sotirios D. Georgopoulos
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W1638992764